ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the area of chronic myeloid leukemia (CML), the knowledge that BCR-ABL is the genetic mutation that drives the disease in most patients with CML, which led to the development of a targeted agent that improved survival outcomes in patients (37).